Benefits Of Timely Care In Pancreatic Cancer: A Systematic Review To Navigate Through The Contradictory Evidence

References

• Freeman HP, Rodriguez RL. History and principles of patient navigation. Cancer. 2011;117(S15):3537–3540. doi:10.1002/cncr.v117.15s21780087
   PubMedGoogle Scholar
• Gorin SS, Haggstrom D, Han PKJ, et al. Cancer care coordination: a systematic review and meta-analysis of over 30 years of empirical studies. Ann Behav Med. 2017;51(4):532–546. doi:10.1007/s12160-017-9876-228685390
   PubMed Web of Science ®Google Scholar
• Department of Health, The NHS Cancer Plan. 2000 Available from: http://webarchive.nationalarchives.gov.uk/20130222181549/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4014513.pdf Accessed 66, 2019.
   Google Scholar
• Wilkens J, Thulesius H, Schmidt I, et al. The 2015 national cancer program in Sweden: introducing standardized care pathways in a decentralized system. Health Policy. 2016;120(12):1378–1382. doi:10.1016/j.healthpol.2016.09.00827823827
   PubMed Web of Science ®Google Scholar
• Sharpe D, Williams RN, Ubhi SS, et al. The “two-week wait” referral pathway allows prompt treatment but does not improve outcome for patients with oesophago-gastric cancer. Eur J Surg Oncol. 2010;36(10):977–981. doi:10.1016/j.ejso.2010.07.00220702059
   PubMed Web of Science ®Google Scholar
• Aslam MI, Chaudhri S, Singh B, et al. The “two-week wait” referral pathway is not associated with improved survival for patients with colorectal cancer. Int J Surg. 2017;43:181–185. doi:10.1016/j.ijsu.2017.05.04628600231
   PubMed Web of Science ®Google Scholar
• Meechan D, Gildea C, Hollingworth L, et al. Variation in use of the 2-week referral pathway for suspected cancer: a cross-sectional analysis. Br J Gen Pract. 2012;62(602):e590–7. doi:10.3399/bjgp12X65455122947579
   PubMed Web of Science ®Google Scholar
• Neal RD, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer. 2015;112(Suppl S1):S92–S107. doi:10.1038/bjc.2015.4825734382
   PubMedGoogle Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Noone AM, Howlader N, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975–2015, National Cancer Institute. Bethesda, MD; 2018 Available from: https://seer.cancer.gov/csr/1975_2015/. Accessed June 6, 2019.
   Google Scholar
• Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6(4):321–337. doi:10.1177/1756283X13478680
   PubMed Web of Science ®Google Scholar
• Kenner BJ, Go VLW, Chari ST, et al. Early detection of pancreatic cancer: the role of industry in the development of biomarkers. Pancreas. 2017;46(10):1238–1241. doi:10.1097/MPA.000000000000093928953187
   PubMed Web of Science ®Google Scholar
• Fric P, Škrha J, Šedo A, et al. Precursors of pancreatic cancer. Eur J Gastroenterol Hepatol. 2017;29(3):e13–e18. doi:10.1097/MEG.000000000000081028009716
   PubMed Web of Science ®Google Scholar
• Yu J, Blackford AL, Dal Molin M, et al. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut. 2015;64(11): gutjnl-2014-308653.
   Web of Science ®Google Scholar
• Ahn SJ, Choi SJ, Kim HS. Time to progression of pancreatic cancer: evaluation with multi-detector computed tomography. J Gastrointest Cancer. 2017;48(2):164–169. doi:10.1007/s12029-016-9876-727699624
   PubMedGoogle Scholar
• Mehrara E, Forssell-Aronsson E, Ahlman H, et al. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res. 2007;67(8):3970–3975. doi:10.1158/0008-5472.CAN-06-382217440113
   PubMed Web of Science ®Google Scholar
• Jooste V, Dejardin O, Bouvier V, et al. Pancreatic cancer: wait times from presentation to treatment and survival in a population-based study. Int J Cancer. 2016;139(5):1073–1080. doi:10.1002/ijc.3016627130333
   PubMed Web of Science ®Google Scholar
• Eshuis WJ, van der Gaag NA, Rauws EAJ, et al. Therapeutic delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary drainage. Ann Surg. 2010;252(5):840–849. doi:10.1097/SLA.0b013e3181fd36a221037440
   PubMed Web of Science ®Google Scholar
• Tokuda Y, Chinen K, Obara H, et al. Intervals between symptom onset and clinical presentation in cancer patients. Intern Med. 2009;48(11):899–905. doi:10.2169/internalmedicine.48.172019483358
   PubMed Web of Science ®Google Scholar
• Crawford SC, Davis JA, Siddiqui NA, et al. The waiting time paradox: population based retrospective study of treatment delay and survival of women with endometrial cancer in Scotland. BMJ. 2002;325(7357):196. doi:10.1136/bmj.325.7357.19612142308
   PubMedGoogle Scholar
• Poruk KE, Firpo MA, Adler DG, et al. Screening for pancreatic cancer: why, how, and who? Ann Surg. 2013;257(1):17–26. doi:10.1097/SLA.0b013e31825ffbfb22895395
   PubMed Web of Science ®Google Scholar
• Schwartz S, Campbell UB, Gatto NM, et al. Toward a clarification of the taxonomy of “bias” in epidemiology textbooks. Epidemiology. 2015;26(2):216–222. doi:10.1097/EDE.000000000000022425536455
   PubMed Web of Science ®Google Scholar
• Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25(1):1–21. doi:10.1214/09-STS31320871802
   PubMed Web of Science ®Google Scholar
• Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20(4):488–495. doi:10.1097/EDE.0b013e3181a819a119525685
   PubMed Web of Science ®Google Scholar
• Pitter JG, Lukács G, Csanádi M, et al. Clinical impact of treatment delay in pancreatic cancer patients revisited. Int J Cancer. 2018;142(12):2621–2622. doi:10.1002/ijc.3126329344934
   PubMed Web of Science ®Google Scholar
• University of York. Centre for Reviews and Dissemination, Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care. University of York, Centre for Reviews & Dissemination; 2009.
   Google Scholar
• Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73:712–716. doi:10.1046/j.1445-2197.2003.02748.x12956787
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.100009719621072
   PubMed Web of Science ®Google Scholar
• Sanjeevi S, Ivanics T, Lundell L, et al. Impact of delay between imaging and treatment in patients with potentially curable pancreatic cancer. Br J Surg. 2016;103(3):267–275. doi:10.1002/bjs.2016.103.issue-326572509
   PubMed Web of Science ®Google Scholar
• Nikou GC, Tsatali E, Th A,et al. The significance of the early detection of clinical symptoms in the overall survival of patients with pancreatic cancer. Ann Gastroenterol. 2001;14(1):33–36.
   Google Scholar
• Swords DS, Mone MC, Zhang C, et al. Initial misdiagnosis of proximal pancreatic adenocarcinoma is associated with delay in diagnosis and advanced stage at presentation. J Gastrointest Surg. 2015;19(10):1813–1821. doi:10.1007/s11605-015-2923-z26286368
   PubMed Web of Science ®Google Scholar
• Gobbi PG, Bergonzi M, Comelli M, et al. The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer. Cancer Epidemiol. 2013;37(2):186–190. doi:10.1016/j.canep.2012.12.00223369450
   PubMed Web of Science ®Google Scholar
• Amr B, Shahtahmassebi G, Briggs CD, et al. Assessment of the effect of interval from presentation to surgery on outcome in patients with peri-ampullary malignancy. HPB (Oxford). 2016;18(4):354–359. doi:10.1016/j.hpb.2015.10.01327037205
   PubMed Web of Science ®Google Scholar
• Healy GM, Redmond CE, Murphy S, et al. Preoperative CT in patients with surgically resectable pancreatic adenocarcinoma: does the time interval between CT and surgery affect survival? Abdom Radiol (NY). 2018;43(3):620–628. doi:10.1007/s00261-017-1254-928695235
   PubMed Web of Science ®Google Scholar
• Raptis DA, Fessas C, Belasyse-Smith P, et al. Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer. Surgeon. 2010;8(5):239–246. doi:10.1016/j.surge.2010.03.00120709279
   PubMed Web of Science ®Google Scholar
• McLean SR, KARSANJI D, WILSON J, et al. The effect of wait times on oncological outcomes from periampullary adenocarcinomas. J Surg Oncol. 2013;107(8):853–858. doi:10.1002/jso.2333823625192
   PubMed Web of Science ®Google Scholar
• Marchegiani G, Andrianello S, Perri G, et al. Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma? HPB. 2017. doi:10.1016/j.hpb.2017.10.017
   Web of Science ®Google Scholar
• Yun YH, Kim YA, Min YH, et al. The influence of hospital volume and surgical treatment delay on long-term survival after cancer surgery. Ann Oncol. 2012;23(10):2731–2737. doi:10.1093/annonc/mds10122553194
   PubMed Web of Science ®Google Scholar
• Deriban G, Andreevski B, Mishevski J, et al. Obstructive jaundice caused by pancreatic head malignancies are there predictive factors for successful endoscopic biliary stenting? Prilozi. 2012;33(2):59–71.23425870
   PubMedGoogle Scholar
• Ghadimi BM, Horstmann O, Jacobsen K, et al. Delay of diagnosis in pancreatic cancer due to suspected symptomatic cholelithiasis. Scand J Gastroenterol. 2002;37(12):1437–1439. doi:10.1080/00365520276267132312523594
   PubMed Web of Science ®Google Scholar
• Driedger MR, Dixon E, Mohamed R, et al. The diagnostic pathway for solid pancreatic neoplasms: are we applying too many tests? J Surg Res. 2015;199(1):39–43. doi:10.1016/j.jss.2015.04.02625953217
   PubMed Web of Science ®Google Scholar
• Glant JA, Waters JA, House MG, et al. Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Surgery. 2011;150(4):607–616. doi:10.1016/j.surg.2011.07.04822000171
   PubMed Web of Science ®Google Scholar
• Raman SP, Reddy S, Weiss MJ, et al. Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer. AJR Am J Roentgenol. 2015;204(1):W37–W42. doi:10.2214/AJR.13.1243925539271
   PubMed Web of Science ®Google Scholar
• Mangel L, Tornóczky T, Zemplényi A, et al. Az első onkológiai ellátás időfaktorának szerepe a daganatos betegségek túlélési mutatóiban. Irodalmi áttekintés. Orv Hetil. 2018;159(14):535–546. doi:10.1556/650.2018.3092029611749
   PubMedGoogle Scholar
• Deshwar AB, Sugar E, Torto D, et al. Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis. Ann Pancreat Cancer. 2018;1.
   PubMedGoogle Scholar
• Tanaka S, Kinjo Y, Kataoka Y, et al. Statistical issues and recommendations for noninferiority trials in oncology: a systematic review. Clin Cancer Res. 2012;18(7):1837–1847. doi:10.1158/1078-0432.CCR-11-165322317762
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. ICH Topic E9. Statistical principles for clinical trials. 1998 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002928.pdf, Accessed 66, 2019.
   Google Scholar
• Institute for Healthcare Improvement, IHI triple aim initiative. 2017 Available from: http://www.ihi.org/Engage/Initiatives/TripleAim/Pages/default.aspx. Accessed 66, 2019.
   Google Scholar